Genmab

Genmab Tops Europe's Market: Stock Jumps 13% as Its Cancer Drug Posts 28-Month Survival Data

2026-10-26

Genmab stock: the short answer Genmab shares jumped 13.7% on Monday, October 26, 2026, to the top of Europe's STOXX 600 index , after the Danish biotech reported updated Phase 2 data for its experi...

biotech European stocks Genmab petosemtamab STOXX 600

Corcept Stock Crashes 20% as Genmab's Rina-S Posts Landmark Phase 3 Results in Ovarian Cancer

2026-10-24

Corcept stock fell 20.13% on Friday, October 23, 2026 — because a rival's drug just posted standout Phase 3 results in the exact cancer market Corcept entered this year. Corcept Therapeutics (NASDA...

Corcept CORT Genmab stocks